Subject: MRR
Significant Positive Shift in the Frontotemporal Dementia Market with 23.39% CAGR During the Study Period 2018-2030 Expected by Analysts at DelveInsight
- Upcoming entry of AL001 (Alector), LMTX (TauRx Therapeutics Ltd), and AADvac1 (AXON Neuroscience) is expected to fuel growth of the Frontotemporal Dementia market.
LAS VEGAS, Aug. 4, 2021 /PRNewswire/ -- DelveInsight's Frontotemporal Dementia (FTD) Market report offers detailed information on current treatment practices, emerging drugs, Frontotemporal Dementia market share of the individual therapies, current and forecasted Frontotemporal Dementia market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Some of key pointers from the Frontotemporal Dementia Market report:
- The total Frontotemporal Dementia prevalent cases in the 7MM were estimated to be 50,100 in the 7MM with the USA accounting for the maximum number of FTD prevalent cases.
- The FTD therapy market is currently dominated by off-label use of therapies that provides symptomatic relief instead of targeting the disease at its root cause.
- The only disease-modifying therapy approved in the US include riluzole.
- Frontotemporal Dementia market size in the 7MM was estimated to be USD 133.8 million in 2020 with the US accounting for approximately 57% of the FTD market share.
- FTD pipeline therapies in the different clinical stages of development include TRx0237 (TauRX Pharmaceuticals), AL001 (Alector), AADvac 1 (Axon Neuroscience), among several others.
- Major pharma and biotech players in the FTD market include Alector, Axon Neuroscience, TauRX Therapeutics, and several others.
Download Frontotemporal Dementia Market Snapshot report to understand FTD drug is going to nab the maximum market share @ Frontotemporal Dementia therapy Market Analysis and Forecast
Frontotemporal Dementia: Disease Overview
Frontotemporal Dementia (FTD) refers to a spectrum of clinical syndromes that demonstrate progressive degenerative changes in behavior, personality, language, cognitive skills, and motor function. It is considered a young-onset dementia that occurs between the ages of 45?65, and is the most common dementia in those under the age of 60.
FTD is further subdivided into two categories on the basis of their predominating presentations, namely, the behavioral subtype and language subtype. The Frontotemporal Dementia epidemiological estimates demonstrated that behavioral subtype accounts for about half of the FTD cases. Further, it was observed that out of all the mutations namely MAPT, PGRN, C9ORF72, VCP, CHMP2B, TARDBP, and FUS genes; MAPT mutation is observed to be more prominent in FTD patients.
Frontotemporal Dementia Epidemiological Segmentation
DelveInsight's Frontotemporal Dementia Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:
- Total Frontotemporal Dementia prevalent cases
- Total diagnosed Frontotemporal Dementia prevalent cases
- Total type-specific diagnosed Frontotemporal Dementia prevalent cases
- Subtype-specific cases of Primary Progressive Aphasia, and Mutations associated with FTD
Understand how Frontotemporal Dementia Epidemiological Trends are going to shape by 2030 in 7 Major Markets by downloading @ Frontotemporal Dementia Epidemiology Market Report Summary
Present Frontotemporal Dementia Therapeutic Market Outlook
Frontotemporal Dementia therapy market relies on off-label therapies for the management of neuropsychiatric symptomatic treatment. The treatment approaches include non-pharmacological as well as pharmacological options. The main purpose of non-pharmacological intervention is to prevent disruptive behaviors, provide symptom relief, and lessen caregiver distress while pharmacological therapy options aim at different symptoms such as cognitive symptoms, behavioral symptoms and others. Pharmacologic treatment of cognitive symptoms involves using cholinesterase inhibitors and N-methyl-D-aspartic acid (NMDA) receptor antagonists; for behavioral symptoms, it involves the use of selective serotonin reuptake inhibitors and similar medications while for motor symptoms includes physical, occupational, and speech/swallow therapy.
Frontotemporal Dementia Market: Unmet Needs and Forecasted Scenario
FTD treatment market offers no curative standard options and available symptomatic therapies have limited clinical utility. There is a serious lack of quality evidence from randomized, placebo-controlled clinical trials for most therapies. The Frontotemporal therapy market has no effective therapies for cognitive symptoms and the available ones for behavioral symptoms, there is always a risk of side effects.
Moreover, Frontotemporal Dementia is a highly underdiagnosed condition owing to an inherent difficulty in accurately diagnosing the neurological disorders. An unclear pathology calls for further R&D for the development of effective diagnostic biomarkers and therapies.
However, to bridge the gap between medical needs and treatment options several pharma and biotech companies such as Alector, Axon Neuroscience, TauRX Therapeutics, and several others are working proactively in the domain.
Discover more about the future market share of the therapies @ Frontotemporal Dementia Treatment Market Landscape and Forecast
Frontotemporal Dementia Market Dynamics
Recent years witnessed an increasing trend in an increase in the R&D, influx of key pharma and biotech companies, entry of novel FTD therapies, new diagnosing biomarkers, rising interest in patient-based registries, especially in rare diseases such FTD is expected to support clinical trial enrolment and track patient data in longitudinal and cross-sectional studies is expected to further help grow the Frontotemporal Dementia market size growth.
Know which therapy is expected to score the touchdown first @ Frontotemporal Dementia Therapeutic Pipeline and Market Forecast
Frontotemporal Dementia Pipeline Therapies
- TRx0237: TauRx Therapeutics Ltd
- AL001: Alector
- AADvac1: Axon Neuroscience
- WVE-004: Wave Life Sciences
Learn more about available treatments @ Frontotemporal Dementia Drug Pipeline Therapies
Scope of the Frontotemporal Dementia Market Report
Coverage: 7MM (the US, EU5, and Japan)
Study Period: 2018-30
Key Companies: Alector, Axon Neuroscience, TauRX Therapeutics and several others.
Key Frontotemporal Dementia Pipeline Therapies: TRx0237, AL001, AADvac 1, and several others.
Frontotemporal Dementia Market Segmentation: By Geography, By Frontotemporal Dementia Therapies
Analysis: Comparative and conjoint analysis of Frontotemporal Dementia emerging therapies
Tools used: SWOT analysis, Conjoint Analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.
Case Studies
KOL's Views
Analyst's Views
Drop by to learn more about the future market trends @ Frontotemporal Dementia Market Landscape and Forecast
Table of Contents
1 | Key Insights |
2 | Frontotemporal Dementia Market Report Introduction |
3 | Frontotemporal Dementia Market Overview at a Glance |
4 | Executive Summary of Frontotemporal Dementia |
5 | Frontotemporal Dementia Disease Background and Overview |
6 | Algorithm for Diagnosis of Frontotemporal Dementia |
7 | Frontotemporal Dementia Patient Journey |
8 | Frontotemporal Dementia Epidemiology and Patient Population |
9 | Treatment Algorithm, Current Treatment, and Medical Practices |
10 | Frontotemporal Dementia Epidemiology and Patient Population |
11 | Country Wise Epidemiology of Frontotemporal Dementia |
10 | Frontotemporal Dementia Treatment |
12 | Unmet Needs |
13 | Key Endpoints of Frontotemporal Dementia Treatment |
14 | Frontotemporal Dementia Emerging Therapies |
15 | Frontotemporal Dementia: 7 Major Market Analysis |
16 | Frontotemporal Dementia Market Unmet Needs |
17 | Case Reports |
18 | Frontotemporal Dementia Market Drivers |
19 | Frontotemporal Dementia Market Barriers |
20 | SWOT Analysis |
21 | KOL Reviews |
21 | Appendix |
22 | DelveInsight Capabilities |
23 | Disclaimer |
24 | About DelveInsight |
Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions
Related Reports
DelveInsight's 'Chronic Pain - Market Insights, Epidemiology, and Market Forecast?2030' report.
DelveInsight's "Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast-2030" report.
Dementia With Diabetes Market Forecast
DelveInsight's 'Dementia with Diabetes?Market Insights, Epidemiology and Market Forecast?2030' report.
Parkinson's Disease Market Size Analysis Treatment
DelveInsight's "Parkinson's Disease - Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight's 'Schizophrenia?Market Insights, Epidemiology, and Market Forecast?2030' report.
Amyotrophic Lateral Sclerosis Als Market
DelveInsight's "Amyotrophic lateral sclerosis (ALS) - Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight's "Ataxia - Market Insights, Epidemiology, and Market Forecast-2030" report.
Related Posts
Eye Disorders Treatment Market
Endoscopy Fluid Management Systems in the MedTech Market
Market Heats Up as Managing Benign Prostatic Hyperplasia Through Devices Gains Traction
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
These press releases may also interest you
|
News published on and distributed by:
